Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector
Reexamination Certificate
2006-12-29
2009-12-08
Huynh, Phuong (Department: 1644)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
C424S185100, C424S193100, C424S275100, C530S350000, C536S023100
Reexamination Certificate
active
07628990
ABSTRACT:
The invention provides classes of immunomodulatory compositions which comprise an average of one or more immunostimulatory sequence (ISS) containing polynucleotide conjugated, or attached, to antigen. The extent of conjugation affects immunomodulatory properties, such as extent of antigen-specific antibody form ration, including Th1-associated antibody formation, and thus these various conjugate classes are useful for modulating the type and extent of immune response. The invention also includes methods of modulating an immune response using these compositions.
REFERENCES:
patent: 4458066 (1984-07-01), Caruthers et al.
patent: 4650675 (1987-03-01), Borel et al.
patent: 4849513 (1989-07-01), Smith et al.
patent: 4910300 (1990-03-01), Urdea et al.
patent: 4948882 (1990-08-01), Ruth
patent: 5015733 (1991-05-01), Smith et al.
patent: 5093232 (1992-03-01), Urdea et al.
patent: 5118800 (1992-06-01), Smith et al.
patent: 5118802 (1992-06-01), Smith et al.
patent: 5124246 (1992-06-01), Urdea et al.
patent: 5391723 (1995-02-01), Priest
patent: 5453496 (1995-09-01), Caruthers et al.
patent: 5663153 (1997-09-01), Hutcherson et al.
patent: 5679647 (1997-10-01), Carson et al.
patent: 5723335 (1998-03-01), Hutcherson et al.
patent: 5804566 (1998-09-01), Carson et al.
patent: 5830877 (1998-11-01), Carson et al.
patent: 5843943 (1998-12-01), Carson et al.
patent: 5849719 (1998-12-01), Carson et al.
patent: 5985847 (1999-11-01), Carson et al.
patent: 6174872 (2001-01-01), Carson et al.
patent: 6225292 (2001-05-01), Raz et al.
patent: 6323201 (2001-11-01), Carson et al.
patent: 6426336 (2002-07-01), Carson et al.
patent: 6498148 (2002-12-01), Raz
patent: 6534062 (2003-03-01), Raz et al.
patent: 6552006 (2003-04-01), Raz et al.
patent: 6562798 (2003-05-01), Schwartz
patent: 6562819 (2003-05-01), Carson et al.
patent: 6589940 (2003-07-01), Raz et al.
patent: 6610661 (2003-08-01), Carson et al.
patent: 6613751 (2003-09-01), Raz et al.
patent: 6951845 (2005-10-01), Carson et al.
patent: 7129222 (2006-10-01), Van Nest et al.
patent: 7157437 (2007-01-01), Van Nest
patent: 7183111 (2007-02-01), Van Nest et al.
patent: 7208478 (2007-04-01), Carson et al.
patent: 7223398 (2007-05-01), Tuck et al.
patent: 7250403 (2007-07-01), Van Nest et al.
patent: 2002/0028784 (2002-03-01), Nest
patent: 2002/0086839 (2002-07-01), Raz et al.
patent: 2002/0098199 (2002-07-01), Van Nest et al.
patent: 2002/0107212 (2002-08-01), Nest et al.
patent: 2003/0064064 (2003-04-01), Dina
patent: 2003/0092663 (2003-05-01), Raz
patent: 2003/0109469 (2003-06-01), Carson et al.
patent: 2003/0129251 (2003-07-01), Van Nest et al.
patent: 2003/0203861 (2003-10-01), Carson et al.
patent: 2003/0216340 (2003-11-01), Van Nest et al.
patent: 2004/0006034 (2004-01-01), Raz et al.
patent: 2004/0009942 (2004-01-01), Van Nest
patent: 2004/0092468 (2004-05-01), Schwartz
patent: 2005/0059626 (2005-03-01), Van Nest et al.
patent: 2006/0013811 (2006-01-01), Dina
patent: 2007/0027098 (2007-02-01), Raz et al.
patent: 2007/0060540 (2007-03-01), Van Nest
patent: 2007/0258994 (2007-11-01), Van Nest et al.
patent: 2008/0009459 (2008-01-01), Van Nest et al.
patent: 0 468 520 (1992-01-01), None
patent: 0 468 520 (1992-01-01), None
patent: WO-95/05853 (1995-03-01), None
patent: WO-96/02555 (1996-02-01), None
patent: WO-97/28259 (1997-08-01), None
patent: WO 98/16247 (1998-04-01), None
patent: WO-98/16247 (1998-04-01), None
patent: WO-98/18810 (1998-05-01), None
patent: WO-98/37919 (1998-09-01), None
patent: WO-98/40100 (1998-09-01), None
patent: WO-98/52581 (1998-11-01), None
patent: WO-98/52962 (1998-11-01), None
patent: WO-98/55495 (1998-12-01), None
patent: WO-98/55495 (1998-12-01), None
patent: WO-98/55609 (1998-12-01), None
patent: WO-99/11275 (1999-03-01), None
patent: WO-99/11275 (1999-03-01), None
patent: WO-99/33488 (1999-07-01), None
patent: WO-99/33488 (1999-07-01), None
patent: WO-99/33868 (1999-07-01), None
patent: WO-99/33868 (1999-07-01), None
patent: WO-99/51259 (1999-10-01), None
patent: WO-99/51259 (1999-10-01), None
patent: WO-99/56755 (1999-11-01), None
patent: WO-99/62923 (1999-12-01), None
patent: WO-99/62923 (1999-12-01), None
patent: WO-00/16804 (2000-03-01), None
patent: WO-00/21556 (2000-04-01), None
patent: WO-00/69861 (2000-11-01), None
Van Uden et a, J Allergy Clin Immunol 104: 902-910, 1999.
Yamada et al, J Immunology 169: 5590-5594, 2002.
Tsunoda et al, Brain Pathol 9(3): 481-93, Jul. 1999.
Segal et al, J Immunology 164: 5683-5688, 2000.
Kandimalla et al, Bioconjugate Chem 13: 966-974, 2002.
Klinman et al, Vaccine 17: Jan. 19-25, 1999.
“The Human Retroviruses and AIDS 1998 Compendium” pp. 1-3 (Contents Part I, I-1, II-4), “Direct Submission” at http://hiv-web.lanl.gov/HTML/98compendium.html (visited on Feb. 1, 2000).
Agrawal et al. (1986). “Efficient methods for attaching non-radioactive labels to the 5′ ends of synthetic oligodeoxyribonucleotides,”Nucleic Acids Res. 14:6227-6245.
Ahmeida et al. (1993). “Immunopotentiation of local and systemic humoral immune responses by ISCOMs, liposomes and FCA: role in protection against influenza A in mice,”Vaccine11(13):1302-1309.
Aramaki et al. (1995). “Interferon-γ inductive effect of liposomes as an immunoadjuvant,”Vaccine13(18):1809-1814.
Asanuma et al. (1996). “Cross-protection against influenza virus infection in mice vaccinated by combined nasal/subcutaneous administration,”Vaccine13(1):3-5.
Atherton et al. (1981). “Synthesis of a 21-residue fragment of human proinsulin by the polyamide solid phase method,”Hoppe-Seylers Z. Physiol. Chem. 362:833-839.
Ausubel, F.M. et al. eds. (1995).Current Protocols in Molecular Biology, vol. I, Supplement 40, John Wiley & Sons, Inc., pp. ii-xii (Table of Contents Only).
Ballas et al. (1996). “Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA,”J. Immunol. 157:1840-1845.
Beaucage, Serge L. (1993). “Oligodeoxyribonucleotide Synthesis” Chapter 3in Protocols for Oligonucleotides and Analogs, Synthesis and Properties, Agrawal (ed.), Humana Press: Totowa, NJ, pp. 33-61.
Benoit et al. (1987). “Peptides. Strategies for antibody production and radioimmunoassays,”Neuromethods6:43-72.
Bischoff et al. (1987). “Introduction of 5′-terminal functional groups into synthetic oligonucleotides for selective immobilization,”Analytical Biochemistry164:336-344.
Blanks, Robert and McLaughlin, Larry W. (1988). “An oligodeoxynucleotide affinity column for the isolation of sequence specific DNA binding proteins,”Nucleic Acids Res. 16(21):10283-10299.
Bliss et al. (1996). “IL-12, as an adjuvant, promotes a T helper 1 cell, but does not suppress a T helper 2 cell recall response,”J. Immunol. 156:887-894.
Bohle et al. (1999). “Oligodeoxynucleotides containing CpG motifs induce IL-12, IL-18, and IFN-γ production in cells from allergic individuals and inhibit IgE synthesis in vitro,”Eur. J. Immunol. 29:2344-2353.
Boujrad et al. (1993). “Inhibition of hormone-stimulated steroidogenesis in cultured Leydig tumor cells by a cholesterol-linked phosphorothioate oligodeoxynucleotide antisense to diazepam-binding inhibitor,”Proc. Natl. Acad. Sci. USA90:5728-5731.
Branda et al. (1993).“Immune stimulation by an antisense oligomer complementary to therevgene of HIV-1,”Biochem. Pharmacol. 45(10):2037-2043.
Branda et al. (1996). “Amplification of antibody production by phosphorothioate oligodeoxynucleotides,”J. Lab. Clin. Med. 128(3):329-338.
Braun et al. (1988). “Immunogenic duplex nucleic acids are nuclease resistant,”J. Immunol. 141:2084-2089.
Brazolot Millan et al. (1998) “CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice,”Proc. Natl. Acad. Sci. USA95:15553-15558.
Breiteneder et al. (1989). “The gene coding for the major birch pollen allergenBetvlis highly ho
Tuck Stephen F.
Van Nest Gary
Dynavax Technologies Corporation
Huynh Phuong
Morrison & Foerster / LLP
LandOfFree
Immunomodulatory compositions containing an... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Immunomodulatory compositions containing an..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunomodulatory compositions containing an... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4083454